Skip to content
Peptidepedia

SS-31 (Elamipretide) Results: Timeline, Before & After & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Results Timelines

Hours to Days:

  • Acute improvements in exercise tolerance and reduced fatigue
  • Enhanced post-exercise recovery
  • Initial reductions in oxidative stress markers

Weeks 1–4:

  • Measurable improvements in cardiac function parameters
  • Increases in exercise capacity (e.g., 6-minute walk distance)
  • Changes in circulating oxidative stress biomarkers
  • Subjective improvements in energy and cognitive clarity reported anecdotally

Weeks 4–12+:

  • Structural mitochondrial improvements including enhanced biogenesis
  • Progressive gains in tissue function across cardiac, renal, and skeletal muscle systems
  • Continued functional capacity improvements in disease populations
The distinction between acute (hours) and structural (months) benefits reflects two separate mechanisms: immediate cardiolipin stabilization affecting current mitochondrial efficiency, and longer-term biogenesis effects requiring PGC-1α-driven mitochondrial synthesis.

Frequently Asked Questions

Acute improvements in energy and exercise tolerance may appear within hours of administration. Measurable changes in cardiac function, exercise capacity, and oxidative stress biomarkers typically emerge over 1–4 weeks. Structural mitochondrial improvements, including enhanced biogenesis and improved tissue function, develop over months of continued treatment.

Cycling necessity is not scientifically established. Clinical trials used continuous dosing for up to 36 weeks without apparent tolerance development. Some users implement 8-weeks-on, 4-weeks-off protocols precautionally, but this practice is not supported by clinical evidence.

Clinical trials lasting up to 36 weeks have not revealed significant safety concerns. No serious adverse events have been definitively attributed to SS-31 in published trials. However, long-term safety data in healthy populations remains limited, and individuals sourcing SS-31 from unregulated research chemical suppliers face contamination risks.

Lyophilized (powder) form should be stored at -20°C for long-term storage, or at 2–8°C for shorter-term storage of several months. Protect from light and moisture. Once reconstituted with bacteriostatic water, store at 2–8°C (refrigerator) and use within 28 days. Discard if the solution becomes cloudy or discolored.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050.
  2. Birk AV, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261.
  3. Daubert MA, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail. 2017;10(12):e004230.
  4. Butler J, et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail. 2020;26(5):429-437.
  5. Thompson R, et al. Current and future treatment approaches for Barth syndrome. J Inherit Metab Dis. 2022;45(1):17-28.
  6. Karaa A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221.
  7. Stealth BioTherapeutics. Elamipretide Development Program.
  8. Sabbah HN, et al. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circ Heart Fail. 2016;9(2):e002206.
  9. Gibson CM, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016;37(16):1296-1303.
←Read the full SS-31 (Elamipretide) guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”